Merck
CN
  • Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.

Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.

Arteriosclerosis, thrombosis, and vascular biology (2009-05-23)
Tony E Walshe, Vandana S Dole, Arindel S R Maharaj, Ian S Patten, Denisa D Wagner, Patricia A D'Amore
摘要

Motivated by the central roles that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-beta play in the assembly and maintenance of the vasculature, we examined the impact of systemic VEGF or TGF-beta signal inhibition on endothelial activation as detected by leukocyte-endothelial interactions. VEGF or TGF-beta inhibition, accomplished using adenovirus expression of soluble Flt1 (Ad-sFlt1) or soluble endoglin (Ad-sEng), resulted in a significant increase in the number of leukocytes rolling along the mesenteric venous endothelium and a significant decrease in rolling velocity in Ad-sEng mice. Neutralization of VEGF or TGF-beta resulted in endothelial surface expression of P-selectin and impaired peripheral vasodilatation. Neither inhibition of VEGF nor TGF-beta was associated with platelet or leukocyte activation, as detected by the activation markers platelet P-selectin and the active integrin alphaIIbbetaIII, or by leukocyte expression of L-selectin. Soluble vascular cell adhesion molecule (VCAM)-1 and E-selectin were increased in sEng-expressing mice, indicating higher levels of these adhesion receptors. VEGF or TGF-beta neutralization leads to impaired endothelium-mediated vasodilatation and elevated expression of surface adhesion molecules, resulting in increased leukocyte adhesion. These results indicate an essential role for both VEGF and TGF-beta in maintaining the endothelium in a nonactivated state and have implications for therapeutic approaches that neutralize VEGF or TGF-beta.

材料
货号
品牌
产品描述

Sigma-Aldrich
SP600125, ≥98% (HPLC)
Sigma-Aldrich
PD 169316, ≥98% (HPLC), solid
Sigma-Aldrich
3-(2-Aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedione hydrochloride, powder, ≥98% (HPLC)